- Trial phase
- Approved
- Time to market
- Already approved and marketed since October 2013. First generic entered the US market on October 5, 2026.
- Why 3/10
- ADEMPAS is already approved and commercialized with no pending regulatory decision or pivotal readout. The next material event was the first generic launch on October 5, 2026, which has already occurred. No hard dated binary catalyst is scheduled in the next ~12 months.
The first generic riociguat launched on October 5, 2026, which will erode Adempas sales and Merck's alliance revenue share over time. Merck reports Adempas/Verquvo alliance revenue as a combined line item in its quarterly filings; watch for declining contributions in upcoming earnings. No binary catalysts remain for this mature, approved drug.
Price Chart
Executive Summary
ADEMPAS (riociguat) is an FDA-approved oral drug for two forms of pulmonary hypertension, developed and primarily marketed by Bayer AG. Merck & Co. (MRK) has a financial interest through a 2014 worldwide collaboration with Bayer, under which Merck receives a share of profits from Adempas and Verquvo sales in Bayer's territories. Adempas generated approximately EUR 745 million (~USD 850 million) in global sales in 2025. On October 5, 2026, Zydus/MSN launched the first generic riociguat in the US, following the loss of US patent protection. For Merck, Adempas alliance revenue is a very small component (combined with Verquvo at ~$126 million in Q2 2025) of a $65 billion revenue base, making this drug a negligible driver for MRK stock.
How It Works
Riociguat is a soluble guanylate cyclase (sGC) stimulator. It works by helping blood vessels relax and widen, which lowers blood pressure in the lungs and improves the heart's ability to pump blood. It is taken as an oral tablet.
Trial Status
ADEMPAS was FDA-approved on October 8, 2013, for two indications: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4). It is a commercially marketed product. A Phase 2 trial in pulmonary hypertension with left ventricular systolic dysfunction was terminated. No pivotal trials are ongoing.
The Two-Sided Case
Upcoming Catalysts
- No binary catalysts remain for this approved, mature drug. The key recent event was the first generic launch on October 5, 2026. Watch for quarterly alliance revenue declines in Merck's earnings reports as generic competition takes effect.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report